Lumateperone: all 34 studies that test it

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Caplyta Versus Placebo for Adults With Social Anxiety DisorderRecruitingNCT07799493Phase 4
• A Study of Lumateperone Versus Placebo in Participants With Major Depressive DisorderNot yet recruitingNCT07747389Phase 3
• Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency DisorderRecruitingNCT07734103Phase 2
• The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar DepressionRecruitingNCT07699445Phase 4
• This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse EffectsNot yet recruitingNCT07676669Phase 4
• Lumateperone for Late-Life DepressionRecruitingNCT07623135Phase 3
• Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life AbuseNot yet recruitingNCT07369115Phase 4
• Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.RecruitingNCT06482554Phase 3
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsRecruitingNCT06372964Phase 3
• Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderRecruitingNCT06229210Phase 3
• Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With SchizophreniaRecruitingNCT06174116Phase 4
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderRecruitingNCT05850689Phase 3
• Caplyta in Borderline Personality DisorderCompletedNCT05356013Phase 2Results posted
• An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT05061719Phase 3Results posted
• Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT05061706Phase 3Results posted
• Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT04985942Phase 3Results posted
• Lumateperone for the Prevention of Relapse in Patients With SchizophreniaCompletedNCT04959032Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT04779177Phase 1Results posted
• Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderCompletedNCT04285515Phase 3Results posted
• ITI-007 (Lumateperone Tosylate) for SchizophreniaTerminatedNCT03817528Phase 2Results posted
• Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted GloballyCompletedNCT03249376Phase 3Results posted
• ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's DiseaseTerminatedNCT02817906Phase 3Results posted
• Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar DepressionCompletedNCT02600507Phase 3Results posted
• Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar DepressionCompletedNCT02600494Phase 3Results posted
• A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of TreatmentCompletedNCT02469155Phase 3Results posted
• A Trial to Assess the Antipsychotic Efficacy of ITI-007CompletedNCT02282761Phase 3Results posted
• Study of a Novel Antipsychotic ITI-007 in SchizophreniaCompletedNCT01499563Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT06627413Phase 1
• Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum DisorderCompletedNCT06557902Phase 1
• Study of Lumateperone in the Treatment of Patients With Bipolar ManiaCompletedNCT06462612Phase 3
• Study of Lumateperone in the Acute Treatment of Patients With Bipolar ManiaCompletedNCT06462586Phase 3
• Relationship Between Efficacy of Lumateperone and Brain Glutamate and DopamineWithdrawnNCT05890768Phase 4
• Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable SchizophreniaCompletedNCT02288845Phase 2
• Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With DementiaCompletedNCT02078310Phase 1/2

← Lumateperone overview